2012美国医师协会口服药物治疗2型糖尿病临床实践指南解读被引量：2

下载PDF

导出

摘要美国医师协会(American College of physicians,ACP)依据循证医学证据,比较口服降糖药的作用及安全性,提出了《2012口服药物治疗2型糖尿病临床实践指南》(以下简称该指南)。该指南是通过对Medline、EMBASE检索到的及Cochrane Central进行过注册的,在1966～2010年进行的,以英文发表的控制研究进行分析制定的。在该指南中,对临床结局的评估包括全因死亡率、心血管事件的发病率及致死率、脑血管事件的发病率、神经病变、肾脏病变、视网膜病变等。这一指南在证据选择及推荐方面遵循美国医师协会的指定系统进行。推荐1:口服降糖药应该在为控制高血糖所进行的生活方式调整已经到位的基础上给予。推荐2:对绝大多数2型糖尿病患者应用单药二甲双胍进行血糖控制。推荐3:在生活方式调整及单药二甲双胍治疗失败的基础上,加用第二种口服降糖药。

作者刘彦君

机构地区中国人民解放军第

出处《中国医学前沿杂志（电子版）》 2012年第9期52-57,共6页 Chinese Journal of the Frontiers of Medical Science(Electronic Version)

关键词二甲双胍单药治疗降糖药物型糖尿病磺脲类药物噻唑烷二酮口服降糖药临床实践指南口服药物治疗医师美国美利坚合众国北美洲

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献38

1National Diabetes Information Clearinghouse (NDIC).Diabetes Overview.NIH Publication No.09-3873,2008.
2Centers for Disease Control and Prevention.National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States,2011[M]Atlanta:Department of Health and Human Services.
3Alexander GC;Sehgal NL;Moloney RM.National trends in treatment of type 2 diabetes mellitus,1994-2007[J]Archives of Internal Medicine,2008(19):2088-2094.
4Bennett WL;Maruthur NM;Singh S.Comparative effectiveness and safety of medications for type 2 diabetes:an update including new drugs and 2-drug combinations[J]Annals of Internal Medicine,2011(09):602-613.
5Bennett WL;Wilson LM;Bolen S.Oral diabetes medications for adults with type 2 diabetes: an update[M]Rockville,MD:Agency for Healthcare Research and Quality,2011.
6Kahn SE;Haffner SM;Heise MA.Glycemic durability of rosiglitazone,metformin,or glyburide monotherapy[J]New England Journal of Medicine,2006(23):2427-2443.
7Evans JM;Ogston SA;Emslie-Smith A.Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes:a comparison of patients treated with sulfonylureas and metformin[J]Diabetologia,2006(05):930-936.
8Fisman EZ;Tenenbaum A;Boyko V.Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up7-year follow-up</a>[J].Clinical Cardiology,2001(02):151-158.
9Johnson JA;Majumdar SR;Simpson SH.Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes[J]Diabetes Care,2002(12):2244-2248.
10Johnson JA;Simpson SH;Toth EL.Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes[J]Diabetic Medicine,2005(04):497-502.